Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 13/20 | 0.65 |
| ▸ | KDR | P35968 | 4/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.61 |
| ▸ | MERTK | Q12866 | 3/20 | 0.60 |
| ▸ | MET | P08581 | 7/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | LYN | P07948 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HCK | P08631 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771206 | 0.92 | AXL (0.74) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL4779377 | 0.90 | AXL (0.73) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL4779528 | 0.88 | AXL (0.67) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL21200973 | 0.87 | AXL (0.83) | AXLKDRMERTKMETAURKA | |
| SCHEMBL30152432 | 0.87 | AXL (0.83) | AXLKDRMERTKMETAURKA | |
| SCHEMBL1897312 | 0.86 | AXL (0.66) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL371648 | 0.81 | PDGFRA (0.84) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL1897070 | 0.81 | AXL (0.82) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL24142383 | 0.79 | PDGFRA (0.79) | AXLKDRPDGFRAMERTKMET | |
| SCHEMBL5824367 | 0.79 | PDGFRA (0.79) | AXLKDRPDGFRAMERTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1777218-B1 | Process for the preparation of 4-phenoxy quinoline derivatives | EISAI R&D MAN CO LTD (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | AXL 515/4885KDR 22/4885PDGFRA 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.